SCHEDULE 13G/A: Vanguard Group Reduces Stake in Achieve Life Sciences to Below 5%
Beneficial Ownership Report
The Vanguard Group has filed an amended Schedule 13G, disclosing a reduction in its beneficial ownership of Achieve Life Sciences Inc. common stock to 4.95%.
Summary
- The Vanguard Group, an investment adviser based in Pennsylvania, reported its beneficial ownership in Achieve Life Sciences Inc. common stock.
- As of March 31, 2025, Vanguard's aggregate beneficial ownership stands at 1,717,014 shares.
- This represents 4.95% of the total class of common stock, placing their ownership below the 5% threshold.
- Vanguard holds sole voting power over 0 shares, shared voting power over 24,505 shares, sole dispositive power over 1,677,701 shares, and shared dispositive power over 39,313 shares.
- The filing certifies that the securities are held in the ordinary course of business and not for the purpose of influencing control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of a passive ownership stake. While the reduction below 5% could be seen as slightly negative, the filing itself is routine and states the holding is in the ordinary course of business, leading to a neutral to slightly negative sentiment.
Negatives
- The Vanguard Group's beneficial ownership in Achieve Life Sciences Inc. has decreased to 4.95%, falling below the 5% threshold, which could be interpreted as a reduction in institutional interest.
Future Outlook
NA
Industry Context
This filing is a routine disclosure by a large institutional investor, The Vanguard Group, regarding its passive ownership stake in a publicly traded company. Such filings provide transparency on significant ownership positions but do not typically reflect broader industry trends or competitive dynamics.
Stakeholder Impact
- Shareholders: The reduction in Vanguard's stake below 5% might lead to questions about institutional confidence, potentially influencing investor sentiment.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of event which requires filing of this statement |
| 04/30/2025 | Date of filing and signature by The Vanguard Group |
Keywords
Achieve Life Sciences Inc., Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.